Lp-PLA2 Activity Testing: The Clinical and Laboratory Perspective

TUESDAY, NOVEMBER 24, 2015  |  2 – 3 pm CST

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker of atherosclerosis and is often referred to by the trademark name “The PLAC Test.” Lp-PLA2 is an enzyme produced mainly by monocytes and macrophages that converts phosphotidylcholine into 2 proinflammatory and proatherogenic molecules: nonesterified fatty acids (NEFA) and lysophosphatidylcholine (LPC). It is also found in the circulation bound to low-density lipoprotein and several studies have shown that patients with high levels of Lp-PLAin the blood are at higher risk of a cardiovascular event such as myocardial infarction or stroke.

This one-hour webinar will examine Lp-PLA2 and the benefits of ordering the Lipoprotein-Associated Phospholipase A2 Activity Test (Mayo ID: PLACA) offered by Mayo Medical Laboratories.

brentwestra

brentwestra

Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.

Leave a Reply

Your email address will not be published. Required fields are marked *